Summary
A new sustained-release tablet formulation of procainamide has been tested in 11 patients with chronic ventricular arrhythmias. At 6 h dosing intervals the fluctuations in plasma procainamide concentrations were equal to or less than those found after treatment at the 3 hourly intervals necessary with conventional tablets of Pronestyl®. It was concluded that the sustained release preparation ought to be more convenient for maintenance therapy with procainamide, as it permitted treatment at intervals of 6 h.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Koch-Weser, J., Klein, S.W., Foo-Canto, L.L., Kastor, J.A., De Sanctis, R.W.: Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. New Engl. J. Med.281, 1253–1260 (1969).
Koch-Weser, J., Klein, S.W.: Procainamide dosage schedules, plasma concentrations, and clinical effects. J. Amer. med. Ass.215, 1454–1460 (1971)
Koch-Weser, J.: Pharmacokinetics of procainamide in man. In: Drug Metabolism in Man (Ed. E.S. Vesell). Ann. N. Y. Acad. Sci.179, 370–382 (1971)
The Pharmacopeia of the United States of America pp. 934 and 950; 18th edit. Bethesda, Maryland: Mac Publishing Co 1970
Münzel, K., Büchi, J., Schultz, O.E.: Galenisches Praktikum p. 466. Stuttgart: Wissenschaftliche Verlags Gesellschaft 1959
Giardina, E.-G.V., Heissenbuttel, R.H., Bigger, J.T.: Intermittent intravenous procaine amide to treat ventricular arrhythmias. Ann. intern. Med.78, 183–193 (1973)
Fremstad, D., Jacobsen, S., Lunde, P.K.M., Landmark, K.H., Myhre, E.: Hvordan bør prokainamid doseres? T. norske Lægeforen.92, 1144–1145 (1972)
Collste, P., Karlsson, E., Norlander, B., Sievers, J., Sjöqvist, F.: Arytmiprofylax med prokainamid: Inadekvat dosering? Läkartidn.69, 47–50 (1972)
Dreyfuss, J., Bigger, J.T. Jr., Cohen, E. C.: Metabolism of procainamide in rhesus monkey and man. Clin. Pharmacol. Ther.13, 366–371 (1972)
Karlsson, E., Norlander, B., Molin, L., Collste, P., Sjöqvist, F.: Samband mellan farmakokinetik och farmakodynamik för prokainamid. In: Symposium “Samband mellan farmakokonetik och farmakodynamik för olika läkemedel”, Mölndal 8.–9. Febr. 1973, AB Hässle, Gothenburg 1973, in press
Wagner, J.G.: Biopharmaceutics and Relevant Pharmacokinetics, p. 292. Hamilton, Illinois: Drug Intelligence Publ. 1971
Lappat, E.J., Cawein, M.J.: A familial study of procainamide—induced systemic lupus erythematosus. A question of pharmacogenetic polymorphism. Amer. J. Med.45, 846–852 (1968)
Anastassiades, T.P., Milliken, J.A.: Lupus-like syndrome, with persistent immunological abnormalities, related to procainamide therapy. Canad. med. Ass. J.107, 312–315 (1972)
Hahn, B.H., Sharp, G.C., Irwin, W.S., Kantor, O.S., Gardner, C.A., Bagby, M.K., Perry, H.M., Osterland, C.K.: Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematous. Ann. intern. Med.76, 365–374 (1972)
Perry, H.M., Tan, E.M., Carmody, S., Sakamoto, A.: Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J. Lab. clin. Med.76, 114–125 (1970)
Zacest, R., Koch-Weser, J.: Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin. Pharmacol. Ther.13, 420–425 (1972)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fremstad, D., Dahl, S., Jacobsen, S. et al. A new sustained-release tablet formulation of procainamide. Eur J Clin Pharmacol 6, 251–255 (1973). https://doi.org/10.1007/BF00644741
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00644741